Rhythm Pharmaceuticals, Inc (RYTM)

Etorro trading 970x250
Rhythm Pharmaceuticals, Inc (RYTM) Logo

About Rhythm Pharmaceuticals, Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company’s lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. Address: 222 Berkeley Street, Boston, MA, United States, 02116

Rhythm Pharmaceuticals, Inc News and around…

Latest news about Rhythm Pharmaceuticals, Inc (RYTM) common stock and company :

Expert Ratings for Rhythm Pharmaceuticals
24 May, 2022 FinancialContent

Analysts have provided the following ratings for Rhythm Pharmaceuticals (NASDAQ:RYTM) within the last quarter: ...

3 Stocks to Buy the Dip Now
20 May, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips You've heard the adage "buy the dip," but not all dips are made equal. There are several strategies for finding worthwhile discounted stocks. The post 3 Stocks to Buy the Dip Now appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

Rhythm Pharmaceuticals vs. Bitcoin: Price Relationship Crosses Threshold
16 May, 2022 FinancialContent

Here at CryptocurrenciesChannel. om, we find it interesting to track various ETF and stock prices versus various digital assets over time.

Is Rhythm Pharmaceuticals (NASDAQ:RYTM) In A Good Position To Invest In Growth?
11 May, 2022 Yahoo! Finance

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Rhythm Pharmaceuticals Announces New Employment Inducement Grants
05 May, 2022 Yahoo! Finance

BOSTON, May 05, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that on May 3, 2022, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 50,730 shares of its common stock to 10 new employees, consisting of inducement stock options to purchase an aggregate of 16,

Stocks That Hit 52-Week Lows On Thursday
05 May, 2022 FinancialContent

During Thursday, 351 stocks hit new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: The largest ...

Rhythm Pharmaceuticals to Present at BofA Securities 2022 Healthcare Conference
04 May, 2022 Yahoo! Finance

BOSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, Chief Executive Officer and President, will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 5:20 p.m. PT (8:20 p.m. ET) in Las Vegas, NV. A live audio webcast of the f

The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
03 May, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Acadia Announces FDA AdComm ...

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates
03 May, 2022 Yahoo! Finance

Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of -7.14% and 38.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Rhythm Pharmaceuticals: Q1 Earnings Insights
03 May, 2022 FinancialContent

Rhythm Pharmaceuticals (NASDAQ:RYTM) reported its Q1 earnings results on Tuesday, May 3, 2022 at 08:00 AM. Here's what ...

Rhythm Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Update
03 May, 2022 Yahoo! Finance

-- Patient identification and physician engagement ongoing in preparation for U.S. commercial launch in June 2022 in BBS and Alström syndrome, pending FDA approval -- -- First commercial patients treated with IMCIVREE® (setmelanotide) in France under paid early access program -- -- First patients enrolled in Phase 3 EMANATE trial and Phase 2 DAYBREAK trial -- -- Multiple abstracts accepted for presentation at ENDO 2022 -- -- Management to host conference call today at 8:30 a.m. ET -- BOSTON, May

Earnings Scheduled For May 3, 2022
03 May, 2022 FinancialContent

Companies Reporting Before The Bell • Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to report earnings for its ...

Rhythm Pharmaceuticals Presents New Data from Phase 3 Trial Evaluating Setmelanotide in Patients with Bardet-Biedl Syndrome (BBS) at the Pediatric Endocrine Society (PES) 2022 Virtual Annual Meeting
02 May, 2022 Yahoo! Finance

-- New data show setmelanotide treatment led to clinically meaningful improvements in lipid parameters, without affecting blood pressure or heart rate in patients with BBS -- -- Additional posters include data from pediatric and adolescent patients enrolled in Phase 3 trial in BBS and qualitative data regarding the impact of hyperphagia on BBS patients and their caregivers -- -- Also presenting cumulative safety data demonstrating setmelanotide was generally safe and well tolerated across 561 pa

Rhythm Pharmaceuticals Q1 2022 Earnings Conference Call On May 3, 2022 At 08:30 AM ET
27 Apr, 2022 FinancialContent

Rhythm Pharmaceuticals (NASDAQ:RYTM) will host a conference call at 08:30 AM ET on May 3, 2022, to discuss Q1 2022 earnings ...

Rhythm Pharmaceuticals to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022
26 Apr, 2022 Yahoo! Finance

BOSTON, April 26, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, May 3, 2022 to report its first quarter 2022 financial results and provide a corporate update. To access the live conference call, please dial (866) 374-5140 (domestic) or (404) 4

Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: Should You Buy?
25 Apr, 2022 Yahoo! Finance

Rhythm Pharmaceuticals, Inc. (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Rhythm Pharmaceuticals (RYTM) Down Due to Study Design Changes
07 Apr, 2022 Yahoo! Finance

Rhythm Pharmaceuticals (RYTM) modifies the design of its two genetic obesity disorder studies to focus on rare patients, thus reducing the targeted population size. RYTM expects to save costs in the process.

51 Biggest Movers From Yesterday
07 Apr, 2022 FinancialContent

Gainers Advent Technologies Holdings, Inc. (NASDAQ: ADN) shares climbed 79.7% to close at $3.63 on Wednesday. Advent Technologies ...

12 Health Care Stocks Moving In Wednesday's Intraday Session
06 Apr, 2022 FinancialContent

Gainers Sunshine Biopharma (NASDAQ:SBFM) shares rose 32.4% to $7.43 during Wednesday's regular session. Sunshine ...

40 Stocks Moving In Wednesday's Mid-Day Session
06 Apr, 2022 FinancialContent

Gainers Advent Technologies Holdings, Inc. (NASDAQ: ADN) shares jumped 77.7% to $3.5950. Advent Technologies and Hyundai Motor ...

Rhythm Pharma Shares Fall After Modifications To Setmelanotide Trials In Rare Diseases of Obesity
06 Apr, 2022 FinancialContent

Rhythm Pharmaceuticals Inc(NASDAQ: RYTM)will modify itsPhase 3 EMANATE and ongoing Phase 2 DAYBREAK trials of ...

Rhythm Pharmaceuticals Optimizes Design of EMANATE and DAYBREAK Clinical Trials to Advance Setmelanotide for Rare Genetic Diseases of Obesity
06 Apr, 2022 Yahoo! Finance

– Phase 3 EMANATE trial to focus on rare patient populations with highest likelihood for success – – First patient enrolled in EMANATE – – Ongoing Phase 2 DAYBREAK trial to focus initially on 10 genes with strongest relevance to the MC4R pathway – – Trial and other program changes extend cash runway into 4Q2023 – BOSTON, April 06, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living

Notable Monday Option Activity: RIOT, RYTM, SKY
21 Mar, 2022 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Riot Blockchain Inc (RIOT), where a total volume of 62,117 contracts has been traded thus far today, a contract volume which is representative of approximately 6.2 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 72.8% of RIOT's average daily trading volume over the past month, of 8.5 million shares..

Noteworthy Friday Option Activity: MDB, TDOC, RYTM
11 Mar, 2022 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in MongoDB Inc (MDB), where a total volume of 8,612 contracts has been traded thus far today, a contract volume which is representative of approximately 861,200 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 60% of MDB's average daily trading volume over the past month, of 1.4 million shares..

Rhythm Pharmaceuticals Earnings Perspective: Return On Capital Employed
04 Mar, 2022 FinancialContent

Benzinga Pro data, Rhythm Pharmaceuticals (NASDAQ:RYTM) reported Q4 sales of $1.82 million. Earnings fell to a loss of $42.87 million, ...

Wren Appoints Bart Henderson as Chief Executive Officer
04 Mar, 2022 FinancialContent

Wren Appoints Bart Henderson as Chief Executive Officer

Rhythm Pharmaceuticals to Present at Cowen & Co. 42nd Annual Health Care Conference
01 Mar, 2022 Yahoo! Finance

BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, Chief Executive Officer and President, will participate in a fireside chat at the Cowen & Co. 42nd Annual Health Care Conference on Tuesday, March 8, 2022 at 10:30 a.m. ET. A live audio webcast of the fireside chat will be avail

Rhythm Pharmaceuticals: Q4 Earnings Insights
01 Mar, 2022 FinancialContent

Rhythm Pharmaceuticals (NASDAQ:RYTM) reported its Q4 earnings results on Tuesday, March 1, 2022 at 08:00 AM. Here's ...

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue Estimates
01 Mar, 2022 Yahoo! Finance

Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of 15% and 6.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
01 Mar, 2022 Yahoo! Finance

-- Preparations continue for U.S. commercial launch in June 2022 in BBS and Alström syndrome, pending FDA approval -- -- First commercial sales of IMCIVREE in Germany and France expected in 2Q2022 – -- Enrollment completed in Phase 2 trial evaluating setmelanotide in patients with hypothalamic obesity -- -- IMCIVREE fourth quarter sales of $1.8M and 2021 sales of $3.2M – -- Management to host conference call today at 8:00 a.m. ET -- BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceutica

Rhythm Pharmaceuticals, Inc (RYTM) is a NASDAQ Common Stock listed in , ,

970x250